RxDoctor Payments Data

Karen Hennessey, MD

Infectious Disease · Bronx, NYNPI 1285783175

Payments from drug & device makers

$16,196in general payments, 2019–2025

Across 100 payments — averaging $161.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$10K
  • Janssen Products, LP$3K
  • Theratechnologies Inc.$1K
  • Gilead$970
  • Shionogi Inc$813
  • Johnson & Johnson$412
  • plus $332 from 6 others

What the payments were for

  • Consulting fees$11,56071%
  • Speaking & faculty fees$7505%
  • Travel & lodging$5754%
  • Food & beverage$2,99218%
  • Education$3192%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,196 in reported general payments places this provider in the 80th percentile of 799 infectious disease providers in New York.

See all infectious disease providers in New York

Medicare billing

Part B allowed, 2024
$2,989
Medicare patients
20
Services billed
23

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala248$961,639
OdefseyEmtricitab/Rilpiviri/Tenof Ala59$203,287
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf26$140,438
JulucaDolutegravir/Rilpivirine33$135,669
TivicayDolutegravir Sodium56$133,563
DescovyEmtricitabine/Tenofov Alafenam33$78,582
CompleraEmtricita/Rilpivirine/Tenof Df19$65,811
DovatoDolutegravir Sodium/Lamivudine21$64,372
PrezcobixDarunavir/Cobicistat24$55,966
TriumeqAbacavir/Dolutegravir/Lamivudi12$42,738
JardianceEmpagliflozin28$35,991
Isentress HdRaltegravir Potassium14$26,567
TrulicityDulaglutide26$25,315
EntrestoSacubitril/Valsartan20$21,668
OzempicSemaglutide13$19,767

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$970$1,040,221281 claims
Viiv Healthcare CompanyJuluca, Tivicay, Dovato, Triumeq$9,807$376,341122 claims
Janssen Products, LPSymtuza$2,707$140,43826 claims
Johnson & JohnsonComplera, Prezcobix$412$121,77743 claims
MerckIsentress Hd, Dulera$25$30,76627 claims
Novo NordiskOzempic$12$19,76713 claims
PfizerEliquis$20$16,98629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 799 infectious disease providers in New York.

Other infectious disease in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →